Cannabidiol Treatment in a Murine Model of Systemic Lupus Erythematosus Accelerates Proteinuria Development

Daphna Katz-Talmor; Shaye Kivity; Miri Blank; Itai Katz; Ori Perry; Alexander Volkov; Iris Barshack; Howard Amital; Yehuda Shoenfeld

Cannabidiol Treatment in a Murine Model of Systemic Lupus Erythematosus Accelerates Proteinuria Development

Isr Med Assoc J. 2018 Dec;20(12):741-745.

Authors

Daphna Katz-Talmor^{1

2}, Shaye Kivity^{1

3

4

5}, Miri Blank^{1

5}, Itai Katz^{1

5}, Ori Perry^{1

5}, Alexander Volkov⁶, Iris Barshack⁶, Howard Amital^{1

7

5}, Yehuda Shoenfeld^{1

5

8}

Affiliations

¹ Zabludowicz Center for Autoimmune Diseases.
² Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
³ Department of Medicine A, Borenstein Talpiot Medical Leadership Program, 2013, Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
⁴ Borenstein Talpiot Medical Leadership Program, 2013, Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
⁵ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁶ Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
⁷ Department of Medicine B, Borenstein Talpiot Medical Leadership Program, 2013, Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
⁸ Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 30550002

No abstract available

MeSH terms

Animals
Antibodies, Antinuclear / immunology*
Cannabidiol / pharmacology*
Disease Models, Animal
Disease Progression
Female
Humans
Immunologic Factors / pharmacology*
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / physiopathology
Mice
Mice, Inbred NZB
Proteinuria / drug therapy*
Proteinuria / etiology
Survival Analysis

Substances

Antibodies, Antinuclear
Immunologic Factors
Cannabidiol